The most common etiology of ataxia in the pediatric population is genetic, with the prevalence of genetic childhood ataxia in Europe estimated at 14.6 per 100,000 population.^[@R1]^ Determining the etiology of childhood-onset ataxia has important clinical relevance, including ending the stressful and costly diagnostic odyssey, guiding genetic counseling, and facilitating precise follow-up and treatment.

The most common causes of hereditary ataxia vary regionally in populations of different genetic backgrounds.^[@R1]^ Owing to the founder effect and genetic isolation, Finland has a unique disease heritage.^[@R2]^ Accordingly, the most common ataxias seen elsewhere in the world, such as Friedreich ataxia, are rare in Finland.

As next generation sequencing (NGS) technologies have evolved, there have been many reports of exome sequencing in single families or single cases with childhood-onset cerebellar ataxia. Many previously reported ataxia cohorts analyze patients with adult or varied age-of-onset^[@R3]^ or are defined by having structural cerebellar abnormalities^[@R4][@R5][@R6]^ instead of the symptom of ataxia. There are a few smaller studies that analyze cohorts of pediatric patients with the symptom of ataxia.^[@R7],[@R8]^

This study applied exome sequencing and a genome-wide genotyping array to examine a cohort of patients with childhood-onset ataxia collected from a single tertiary center, allowing better characterization of the genetic background of molecularly undefined childhood-onset ataxias in Finland. An age limit of 5 years at onset was applied to demarcate a clinical entity within the heterogeneous group of hereditary ataxias and is based on the Human Phenotype Ontology (HPO)^[@R9]^ defining childhood-onset as onset before the fifth birthday.

Methods {#s1}
=======

Patients {#s1-1}
--------

We reviewed all pediatric patients who were diagnosed with ataxia as the primary symptom of their disease in a single tertiary center (Helsinki University Hospital Child Neurology) during years 1999--2018. An overview of the study is shown in [figure 1](#F1){ref-type="fig"}. The exclusion criteria are provided in appendix e-1 ([links.lww.com/NXG/A269](http://links.lww.com/NXG/A269)).

![Study flowchart\
Number of families with children with ataxia syndrome seen in the Helsinki University Hospital Child Neurology Clinic in 1999--2018. Patients were referred from the Helsinki-Uusimaa region (catchment area population ∼1.7 million, ∼30% of the Finnish population). The Helsinki-Uusimaa region is highlighted on the map. GSAMD = Global Screening Array Multi-disease.](NG2019012807f1){#F1}

Thirty-three children from 25 families seen in the Helsinki University Hospital Child Neurology clinic between 1999 and 2018 for the onset of ataxia younger than 5 years had a molecular diagnosis made outside of this study. The etiology included pathogenic variants in the genes *ATXN7* (2 families), *CACNA1A* (4 families), *C12orf65* (2 families), *DNAJC19*, *FOLR1* (2 families), *NARP*, *NKX2-1*, *PDHA1*, *SCN2A*, *SCN8A*, *SLC17A5* (3 families), *SUCLA2*, and *TWNK* (4 families). In addition, a 6.4 Mb deletion in chromosome 10 (10q26.2q26.3) was found to underlie ataxia in 1 patient.

We invited families with children who received a clinical diagnosis of an ataxia syndrome of an unknown etiology and with onset of symptoms before the age of 5 years to participate in the study. We recruited 50 families while 2 families declined participation. In families with multiple affected children, we selected the first child referred to our clinic as the proband. From October 2014 through February 2019, we performed exome sequencing on samples obtained from 50 probands.

Routine genetic screening was not required before entering the study, although single gene or gene-panel testing of known ataxia genes had been performed for some patients before the study. In this regard, if the treating physician suspected a specific genetic etiology, for example, infantile-onset spinocerebellar ataxia, a disease belonging to the Finnish disease heritage, the gene in question may have been tested before recruitment into this study. [Table 1](#T1){ref-type="table"} describes the clinical characteristics and demographics of the cohort. For all patients in the cohort, diagnostic investigations for ataxia had begun during early childhood. The results of a clinical microarray comparative genomic hybridization (CGH) test performed before the study were available for 46% (23/50) of all probands. Twelve patients (24%) were either prescreened or screened during the study for pathologically expanded trinucleotide repeats (appendix e-1, [links.lww.com/NXG/A269](http://links.lww.com/NXG/A269)).

###### 

Demographic and clinical background of the cohort
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Standard protocol approvals, registrations, and patient consents {#s1-2}
----------------------------------------------------------------

The study was approved by the Helsinki University Hospital ethics review board. All patients and/or their legal guardians gave informed consent in accordance with the Declaration of Helsinki.

Phenotyping {#s1-3}
-----------

A child neurologist with expertise in childhood-onset ataxia examined all patients, whereas all available clinical, laboratory, and imaging data were reviewed by several clinicians undertaking the study. Primary phenotypes were mapped to HPO terms^[@R9]^ and included in the in-house semiautomated variant prioritization pipeline.

Sequencing and bioinformatics analysis {#s1-4}
--------------------------------------

We performed exome sequencing on genomic DNA for 50 probands, 2 affected parents, and an affected sibling in 2 families.

The variant calling pipeline of the Finnish Institute of Molecular Medicine was used for the reference genome alignment and variant calling.^[@R10]^ We prioritized recessive-type nonsynonymous variants with a minor allele frequency of less than 0.1% on the Exome Aggregation Consortium (ExAC)^[@R11]^ server. For potential de novo or dominantly inherited variants, heterozygous variants that were not found at all on the ExAC server were prioritized for consideration. We further prioritized variants by their predicted deleterious effect using amino acid conservation and, in the case of potential de novo variants, by gene constraint to mutation according to the framework previously described.^[@R11]^ The prediction tools SIFT^[@R12]^ and Polyphen^[@R13]^ as well as Combined Annotation Dependent Depletion (CADD) C-score^[@R14]^ were used in variant evaluation. Variants with a CADD C-score^[@R14]^ of less than 10 were excluded. Variants were also compared with our in-house database containing 520 exomes.

We classified novel sequence variants using the guidelines provided by the American College of Medical Genetics and Genomics (ACMG).^[@R15]^

Sanger sequencing was used to validate the variants identified by exome sequencing and for segregation analysis. In the case of P12, samples from the child\'s biological parents were unavailable, and as confirmation, western blot was used to confirm the deleterious effect of the variant identified.

Technical information on exome sequencing, a list of the primers used in Sanger sequencing and details of experimental validation of variants identified for P3 and P12, is provided in appendix e-1 ([links.lww.com/NXG/A269](http://links.lww.com/NXG/A269)).

Global screening array analysis {#s1-5}
-------------------------------

We screened for copy number variation and uniparental disomy after exome analysis was negative in 23 probands, for whom there was available DNA, using the 759993 single nucleotide polymorphism (SNP) markers of Illumina Infinium Global Screening Array MD-24 v.2.0 (GSAMD; Illumina, San Diego, CA). Log R ratio and B allele frequency values were generated with GenomeStudio 2.0 software (Illumina), and copy number variation regions were detected with PennCNV software using standard quality control checks.^[@R16]^ Standard quality control of genome-wide genotyping data was performed with PLINK 1.9 software.^[@R17]^

Data availability {#s1-6}
-----------------

The data that support the findings of this study are available on request. The data are not publicly available because of the information that could compromise the privacy of research participants.

Results {#s2}
=======

Diagnostic yield of exome sequencing {#s2-1}
------------------------------------

We obtained a molecular diagnosis for 20 probands (40%) using exome sequencing. We identified 26 diagnostic variants in 16 genes, 13 of which were novel and include a variant in the gene *GPAA1* that was published from this cohort.^[@R18]^ A recessive form of inheritance was found in 9 probands, with 3 of the diagnosed probands having homozygous variants and 6 having compound heterozygous variants. We identified dominant variants in 11 probands, including de novo variants in 8 probands, 2 familial autosomal dominant variants, and a suspicion of parental somatic mosaicism in 1 parent of 1 proband. In all familial cases, there were no pedigrees involving 3 or more generations.

After multidisciplinary evaluation, a novel variant in *COQ8A* and *STUB1* was considered diagnostic for the probands\' ataxia although they remained as variants of uncertain significance as per strict application of the ACMG guidelines.

The diagnostic variants we found are listed in [table 2](#T2){ref-type="table"}. We annotated variants to the Ensembl^[@R19]^ canonical transcript for each gene. Allele frequencies are reported as found in the Genome Aggregation Database.^[@R20]^

###### 

Diagnostic variants underlying the patients\' ataxia
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Diagnostic yield of genome-wide genotyping array {#s2-2}
------------------------------------------------

We uncovered 2 copy number variants (CNVs) that we considered pathogenic using the GSAMD genome-wide genotyping array. For P21, we identified a heterozygous 570 kb deletion in the 10q26.3 region (chr10:131538728-132108832), encompassing the genes *EBF3*, *GLRX*, *LINC00959*, and part of *MGMT*. The same deletion had already been identified in the patient\'s clinical molecular karyotype when analyzed in 2015 but was, at that time, considered to be of uncertain significance. The parents of the patient were screened for the mutation, and it was found to be de novo. The GSAMD finding prompted re-evaluation of the deletion. Since 2017, haploinsufficiency of *EBF3* has been reported to cause hypotonia, ataxia, and delayed development syndrome (MIM \#617330).

For P22, we identified a heterozygous 1.2 kb deletion in *SLC2A1* (chr1:43392250-43393465), encompassing most of exon 9 and all of exon 10. Mutations in *SLC2A1* are known to cause GLUT1 deficiency syndrome 1 (MIM \#606777) and GLUT1 deficiency syndrome 2 (MIM \#612126). Multiexon deletions in *SLC2A1* are known to cause disease.^[@R21]^ The GSAMD finding was confirmed with multiplex ligation-dependent probe amplification in a clinical laboratory and confirmed to be de novo.

Patient phenotypes and effect on clinical management {#s2-3}
----------------------------------------------------

The findings of the study affected the clinical management of multiple patients. Table e-1 ([links.lww.com/NXG/A268](http://links.lww.com/NXG/A268)) describes the patient phenotypes and possible effects on clinical treatment and management.

Variants of uncertain significance in ataxia genes {#s2-4}
--------------------------------------------------

Four probands had a variant of uncertain significance in a gene previously implicated in ataxia, listed in [table 3](#T3){ref-type="table"}.

###### 

Variants of uncertain significance for the probands\' ataxia
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Gene of uncertain significance {#s2-5}
------------------------------

We found a heterozygous de novo missense variant for P27 in a gene not previously linked to ataxia, *MED23* ([figure 2A](#F2){ref-type="fig"}). The patient has hypotonia, tremor, and ataxia that developed at the age of 1.5 years. A detailed phenotypic description for P27 is in appendix e-1 ([links.lww.com/NXG/A269](http://links.lww.com/NXG/A269)). *MED23* encodes a transcription factor in which recessive mutations are known to cause autosomal recessive nonsyndromic mental retardation-18 (MIM \#614249).^[@R22]^ De novo status was confirmed by DNA fingerprinting of the patient and parents using 7 microsatellite markers. *MED23* has a high constraint for missense mutations (missense Z: 4.53556). The variant, chr6g.131919485A\>G, c.2549T\>C, p.(Leu850Pro) has a high CADD C-score (28.6) and causes the change of a conserved amino acid ([figure 2B](#F2){ref-type="fig"}).

![MED23 variant\
The P27 heterozygous variant, chr6g.131919485A\>G, c.2549T\>C, p.(Leu850Pro) in *MED23* (A) causes the change of a conserved amino acid (B).](NG2019012807f2){#F2}

Discussion {#s3}
==========

Exome sequencing is a robust diagnostic method for childhood-onset ataxias manifesting before the age of 5. We found disease-causing mutations in many different genes in this cohort despite the defined age at onset, phenotypical overlap between patients, the founder effect, and genetic isolation in the Finnish population. This is surprising because Finland has a unique disease heritage; however, our findings reflect the heterogeneous genetic background of ataxia seen worldwide and the substantial contribution of de novo variants underlying childhood ataxia.

The patients who were investigated with exome sequencing formed a "hard-to-diagnose" cohort, which did not include patients from the same clinic whose genetic diagnosis had previously been made by single gene or panel testing. In this study, the combination of exome sequencing and GSAMD provided a diagnosis for 44% of the investigated families. This is slightly higher than in ataxia cohorts comprising patients with varying ages of disease onset, where an estimated diagnostic rate for exome sequencing is 36%.^[@R3]^ Our diagnostic yield was at the same level as other smaller exome sequencing studies of symptom-based pediatric ataxia (46%--80%).^[@R7],[@R8],[@R23]^

The percentage of genetically diagnosed patients that were found to have a de novo variant underlying their disease in previous studies varied. In the first such published study,^[@R7]^ in a cohort of 28 families (6 consanguineous), 9% had a pathogenic de novo variant. Our study revealed a remarkably higher de novo rate of 45% in patients with previously molecularly undiagnosed childhood-onset ataxia. Other reports include a 25% de novo rate in a study that investigated congenital ataxia in consanguineous families^[@R8]^ and another study^[@R23]^ that found a 42% de novo rate in a pediatric movement disorder cohort including patients with ataxia.

One of the limitations in our study was that in most cases only the proband, and not parents, was sequenced. Trio exome analysis is associated with a higher diagnostic yield compared with single exome analysis in rare Mendelian disorders,^[@R24]^ and trio analysis is especially useful in an early onset, mainly sporadic ataxia cohort.^[@R3]^ However, a large number of de novo mutations were still identified by prioritizing deleterious heterozygous variants using CADD C-scores and gene constraint scores.^[@R11],[@R14]^ Nevertheless, the high burden of de novo variants in this cohort adds to the recommendation of a triosequencing approach. Furthermore, our exome sequencing analysis may have underestimated the number of CNVs and may have overlooked uniparental disomy because their analysis is not straightforward from exome sequencing data. Software that infer copy number variation from exome sequencing data, such as ExomeDepth,^[@R25]^ can have suboptimal specificity and sensitivity, especially in the case of small CNVs spanning one exon.^[@R26]^ In children with developmental delay, a first-tier diagnostic test revealing CNVs has been chromosomal microarray, either with array-based CGH or SNP array.^[@R27]^ Not all copy number variation is revealed even with the combination of microarray CGH and exome sequencing because CNVs at the intragene level will usually be too small to be identified using the microarrays in clinical use. High-resolution microarray or genome sequencing can still better identify CNVs, especially the long indels and small CNVs that are otherwise not found. We found GSAMD to be a cost-effective method to screen for copy number variation and uniparental disomy and to confirm maternity and paternity in suspected de novo cases in a research setting. In the patients examined with GSAMD, 4 had previous findings reported in clinical molecular karyotypes. These previously identified variations had been inherited from an unaffected parent or had otherwise been interpreted to be of uncertain significance. The GSAMD detected all 4 of these CNVs, adding to our confidence in the method.

We did not find any pathologic repeat expansions, such as those underlying Friedreich ataxia or many of the dominant spinocerebellar ataxias, which are poorly detected using NGS technologies. Many of the common spinocerebellar ataxias caused by trinucleotide repeats are rare in Finland, with the exception of spinocerebellar ataxia type 7,^[@R28]^ and are unlikely to be represented in an early-childhood-onset cohort. However, repeat expansions in novel ataxia disease genes are possibly yet to be discovered, and identification of such mutations is likely to be enabled by application of long-read genome sequencing technologies.

NGS techniques have become ubiquitous diagnostic methods in centers studying neurodevelopmental and neurodegenerative disorders. Developing effective diagnostic algorithms requires experience of the utility of these methods as first- or second-line studies. As new genes and broader phenotypes in ataxia continue to be identified, targeted gene panels may overlook recently identified disease genes. In the case of our cohort, many findings would not have been made using the panels available at the time of sequencing. In the case of a negative exome or genome, systematic re-evaluation at a later time point may reveal a diagnosis. Publications of candidate genes potentially causing diseases in humans, as well as internet resources listing rare variants, aid researchers in finding other families with the same disease.

Most Finnish patients with childhood-onset ataxia are candidates for exome or genome sequencing when the phenotype and background do not clearly point to a specific disease entity. Patients in the cohort had medically actionable findings, underscoring the importance of exome, or genome sequencing as a first-line diagnostic method. Concurrently, it is crucial for the clinician to understand the inherent weaknesses of exome sequencing, especially the inefficiency concerning current analysis tools to detect copy number variation and triplet repeats.
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